Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cardiac Surgery Subjects Clear all
Terminated No phase listed Observational

Evaluation of Renal Function in Subjects Who Had Undergone Cardiac Surgery

NCT04654221
View directory record Official record
Conditions
Cardiac Surgery
Interventions
mGFR by iohexol clearance
Diagnostic Test
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Mobile, Alabama • Covina, California • Northridge, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 21, 2026, 7:12 PM EDT
Terminated Not applicable Interventional Results available

REPRISE IV: LOTUS Edge Valve System in Intermediate Surgical Risk Subjects

NCT03618095
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
LOTUS Edge Valve System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
49
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Oct 21, 2026, 7:12 PM EDT
Completed Phase 2 Interventional Results available

A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume

NCT00816023
View directory record Official record
Conditions
Bloodloss, Surgical Procedures, Operative
Interventions
ecallantide, placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 85 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Birmingham, Alabama • Montgomery, Alabama • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2015 · Synced Oct 21, 2026, 7:12 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection

NCT00600483
View directory record Official record
Conditions
Cardiac Surgery, Sternal Wound Infection
Interventions
gentamicin-collagen sponge dipped in saline
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years and older
Enrollment
1,502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
43
States / cities
Birmingham, Alabama • Florence, Alabama • Pasadena, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 21, 2026, 7:12 PM EDT
Completed Phase 2 Interventional Results available

Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery

NCT00888940
View directory record Official record
Conditions
Bloodloss, Surgical Procedures, Operative
Interventions
Ecallantide, Cyklokapron(R)
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 85 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 21, 2026, 7:12 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury (AKI) Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery

NCT03941483
View directory record Official record
Conditions
Acute Kidney Injury (AKI)
Interventions
ASP1128, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
35 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
27
States / cities
Huntsville, Alabama • Tucson, Arizona • Clearwater, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 21, 2026, 7:12 PM EDT
Suspended Phase 2Phase 3 Interventional

Phase II Study To Evaluate The Safety and Efficacy of Hemoglobin Raffimer in Patients Undergoing First Time CABG Surgery

NCT00038454
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Hemolink (hemoglobin raffimer IV solution)
Drug
Lead sponsor
Hemosol
Industry
Eligibility
18 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
19
States / cities
San Francisco, California • Stanford, California • Sarasota, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 7:12 PM EDT
Completed Phase 3 Interventional

Safety and Hemostatic Efficacy of Fibrin Sealant Vapor Heated, Solvent/Detergent Treated (FS VH S/D) Compared With Currently Licensed TISSEEL VH Fibrin Sealant in Subjects Undergoing Cardiac Surgery

NCT00161733
View directory record Official record
Conditions
Cardiac Surgery Requiring Cardiopulmonary Bypass and Median Sternotomy, Cardiopulmonary Bypass, Sternotomy
Interventions
Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D), TISSEEL VH fibrin sealant
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years and older
Timeline
2002 – 2004
U.S. locations
22
States / cities
Phoenix, Arizona • Orange, California • Gainesville, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 21, 2026, 7:12 PM EDT
Completed Phase 4 Interventional Results available

Rapid Sternal Closure System (TALON)

NCT00638014
View directory record Official record
Conditions
Sternal Wound Infection, Mediastinitis
Interventions
Rapid Sternal Closure System, Conventional wire closure
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 2, 2011 · Synced Oct 21, 2026, 7:12 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol

NCT00678834
View directory record Official record
Conditions
End Stage Cardiac Failure, Pulmonary Failure, End Stage Liver Disease, Morbid Obesity, Recalcitrant Epilepsy Requiring Surgery, Healthy Subjects
Interventions
To surgery patients, Tocopherol capsules., Tocotrienol to healthy subjects., To surgery patients, Tocotrienol capsules.
Dietary Supplement
Lead sponsor
Chandan K Sen
Other
Eligibility
21 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 21, 2026, 7:12 PM EDT
Terminated Phase 2 Interventional

Study of INS50589 Intravenous Infusion in Subjects Undergoing Coronary Artery Bypass Grafting (CABG) Involving Cardiopulmonary Bypass

NCT00316212
View directory record Official record
Conditions
Coronary Disease
Interventions
INS50589 Intravenous Infusion
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Timeline
Started 2006
U.S. locations
27
States / cities
Birmingham, Alabama • San Diego, California • Springfield, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 21, 2026, 7:12 PM EDT
Completed Phase 3 Interventional

Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery

NCT00125320
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
RSD1235
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Fort Lauderdale, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 24, 2007 · Synced Oct 21, 2026, 7:12 PM EDT
Completed No phase listed Observational

Implantation of the HeartMate 3 in Subjects With Heart Failure Using Surgical SWIFT HM3 PMS

NCT04548128
View directory record Official record
Conditions
Advanced Refractory Left Ventricular Heart Failure
Interventions
HeartMate 3 Left Ventricular Assist System (HM3 LVAS)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
31
States / cities
Little Rock, Arkansas • Palo Alto, California • Aurora, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 21, 2026, 7:12 PM EDT
Recruiting Phase 1Phase 2 Interventional

Amiodarone-Infused CardiaMend Patches for the Prevention of New-Onset POAF in Cardiac Surgery Subjects

NCT06730828
View directory record Official record
Conditions
Atrial Fibrillation, Postoperative
Interventions
The intervention includes Amiodarone-Infused CardiaMend patches (70mg, 150mg and 300mg)
Combination Product
Lead sponsor
Helios Cardio Inc.
Industry
Eligibility
20 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 21, 2026, 7:12 PM EDT
Completed Phase 2 Interventional Results available

Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing CABG and/or Cardiac Valve Surgery

NCT04564833
View directory record Official record
Conditions
AKI
Interventions
Low Dose RBT-1, High Dose RBT-1, Placebo
Drug
Lead sponsor
Renibus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
18
States / cities
Huntsville, Alabama • Los Angeles, California • Santa Barbara, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Oct 21, 2026, 7:12 PM EDT
Completed Phase 2 Interventional Results available

Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery

NCT00838383
View directory record Official record
Conditions
Cardiac Surgery Subjects, Subjects Undergoing CABG and/or Cardiac Valve Replacement
Interventions
sitaxsentan (Thelin), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
48 Years to 82 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Charleston, South Carolina • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Oct 21, 2026, 7:12 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery

NCT02610283
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
QPI-1002, Placebo
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
20
States / cities
Tucson, Arizona • Gainesville, Florida • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 21, 2026, 7:12 PM EDT
Withdrawn Phase 3 Interventional

A Research Study to Evaluate the Effectiveness of Dexmedetomidine in Preventing Delirium After Heart Surgery

NCT00464763
View directory record Official record
Conditions
Delirium
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
11
States / cities
Loma Linda, California • Towson, Maryland • Grand Blanc, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 21, 2026, 7:12 PM EDT
Recruiting Phase 1 Interventional

Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery

NCT06271265
View directory record Official record
Conditions
Postoperative Pain
Interventions
EXPAREL, bupivacaine
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
0 Years to 6 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Indianapolis, Indiana • St Louis, Missouri • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 21, 2026, 7:12 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery

NCT05126303
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
RMC-035, Placebo
Drug
Lead sponsor
Guard Therapeutics AB
Industry
Eligibility
18 Years to 84 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Fort Wayne, Indiana • Lincoln, Nebraska • Rochester, New York + 5 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 21, 2026, 7:12 PM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery

NCT01777165
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
ABT-719, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
38
States / cities
Danbury, Connecticut • Gainesville, Florida • Jacksonville, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Oct 21, 2026, 7:12 PM EDT
Terminated Phase 4 Interventional Results available

Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery

NCT01765270
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Cardiovascular Disease
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
45 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Birmingham, Alabama • Huntsville, Alabama • Fort Smith, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated May 29, 2015 · Synced Oct 21, 2026, 7:12 PM EDT
Active, not recruiting Not applicable Interventional Results available

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).

NCT01586910
View directory record Official record
Conditions
Severe Aortic Stenosis
Interventions
Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI), Surgical Aortic Valve Replacement (SAVR), Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI)
Device · Procedure
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
Not listed
Enrollment
1,746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
65
States / cities
Phoenix, Arizona • Hollywood, California • La Jolla, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 21, 2026, 7:12 PM EDT
Completed No phase listed Observational

WeighT LOSS Surgery and Comprehensive Cardiometabolic Responses to to EXercise

NCT06576050
View directory record Official record
Conditions
Heart Failure, Obesity, Weight Loss, Heart Failure With Preserved Ejection Fraction
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 21, 2026, 7:12 PM EDT